Exact Mass: 603.3559694

Exact Mass Matches: 603.3559694

Found 211 metabolites which its exact mass value is equals to given mass value 603.3559694, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Lolicine A

C38H53NO5 (603.3923527999999)

Janthitrem E

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0²,¹⁵.0³,¹².0⁶,¹¹.0¹⁸,³⁰.0²⁰,²⁸.0²²,²⁷]hentriaconta-1(17),10,18(30),19,26,28-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)

Janthitrem E is produced by Penicillium janthinellum. Tremorgenic mycotoxi Production by Penicillium janthinellum. Tremorgenic mycotoxin.

Benzonatate

2-[2-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoic acid

C30H53NO11 (603.3618428)

Benzonatate is a non-narcotic oral antitussive (cough suppressant) drug which works by anesthetizing the tissues of the lungs and pleura responsible for the cough reflex. It is chemically related to other ester anesthetics such as procaine. It has an anesthetic (numbing) action similar to that of benzocaine and numbs the stretch sensors in the lungs. It is the stretching of these sensors with breathing that causes the cough. It was approved by the FDA in 1958. R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

Fumonisin AK1

1,2,3-Propanetricarboxylic acid, 1-[13-(acetylamino)-5,10,12-trihydroxy-3-methyl-1-(2-methyl-1-oxohexyl)tetradecyl] ester

C30H53NO11 (603.3618428)

Fumonisin AK1 is produced by Fusarium proliferatum. Production by Fusarium proliferatum.

Gly-Pro-Gly-Arg-Ala-Phe

2-{2-[2-(2-{[1-(2-aminoacetyl)pyrrolidin-2-yl]formamido}acetamido)-5-[(diaminomethylidene)amino]pentanamido]propanamido}-3-phenylpropanoic acid

C27H41N9O7 (603.3128796000001)

1-[1-Butyl-2-oxo-4-[3-(pyridin-3-ylmethoxy)phenyl]-1,8-naphthyridin-3-yl]-3-[2,6-di(propan-2-yl)phenyl]urea

N-[2,6-bis(propan-2-yl)phenyl]-N-(1-butyl-2-oxo-4-{3-[(pyridin-3-yl)methoxy]phenyl}-1,2-dihydro-1,8-naphthyridin-3-yl)carbamimidate

C37H41N5O3 (603.3209236)

PC(2:0/20:3(6,8,11)-OH(5))

(2-{[(2R)-3-(acetyloxy)-2-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H54NO9P (603.3536004)

PC(2:0/20:3(6,8,11)-OH(5)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/20:3(6,8,11)-OH(5)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-hydroxyeicosatetrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

PC(20:3(6,8,11)-OH(5)/2:0)

(2-{[(2R)-2-(acetyloxy)-3-{[(6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoyl]oxy}propyl phosphono]oxy}ethyl)trimethylazanium

C30H54NO9P (603.3536004)

PC(20:3(6,8,11)-OH(5)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(20:3(6,8,11)-OH(5)/2:0), in particular, consists of one chain of one 5-hydroxyeicosatetrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).

Asp Lys Arg Trp

(3S)-3-amino-3-{[(1S)-5-amino-1-{[(1S)-4-carbamimidamido-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}butyl]carbamoyl}pentyl]carbamoyl}propanoic acid

C27H41N9O7 (603.3128796000001)

Asp Lys Trp Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-carboxypropanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C27H41N9O7 (603.3128796000001)

Asp Arg Lys Trp

(3S)-3-amino-3-{[(1S)-1-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pentyl]carbamoyl}-4-carbamimidamidobutyl]carbamoyl}propanoic acid

C27H41N9O7 (603.3128796000001)

Asp Arg Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Asp Trp Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanoic acid

C27H41N9O7 (603.3128796000001)

Asp Trp Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Lys Asp Arg Trp

(3S)-3-{[(1S)-4-carbamimidamido-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}butyl]carbamoyl}-3-[(2S)-2,6-diaminohexanamido]propanoic acid

C27H41N9O7 (603.3128796000001)

Lys Asp Trp Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-3-carboxy-2-[(2S)-2,6-diaminohexanamido]propanamido]-3-(1H-indol-3-yl)propanamido]pentanoic acid

C27H41N9O7 (603.3128796000001)

Lys Arg Asp Trp

(3S)-3-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C27H41N9O7 (603.3128796000001)

Lys Arg Trp Asp

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2,6-diaminohexanamido]pentanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Lys Trp Asp Arg

(2S)-5-carbamimidamido-2-[(2S)-3-carboxy-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]propanamido]pentanoic acid

C27H41N9O7 (603.3128796000001)

Lys Trp Arg Asp

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-indol-3-yl)propanamido]pentanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Arg Asp Lys Trp

(3S)-3-{[(1S)-5-amino-1-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}pentyl]carbamoyl}-3-[(2S)-2-amino-5-carbamimidamidopentanamido]propanoic acid

C27H41N9O7 (603.3128796000001)

Arg Asp Trp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-carboxypropanamido]-3-(1H-indol-3-yl)propanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Arg Lys Asp Trp

(3S)-3-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-{[(1S)-1-carboxy-2-(1H-indol-3-yl)ethyl]carbamoyl}propanoic acid

C27H41N9O7 (603.3128796000001)

Arg Lys Trp Asp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-5-carbamimidamidopentanamido]hexanamido]-3-(1H-indol-3-yl)propanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Arg Arg Ser Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N11O6 (603.3241126)

Arg Arg Trp Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C26H41N11O6 (603.3241126)

Arg Ser Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N11O6 (603.3241126)

Arg Ser Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

Arg Trp Asp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-carboxypropanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Arg Trp Lys Asp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]hexanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Arg Trp Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C26H41N11O6 (603.3241126)

Arg Trp Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

Ser Arg Arg Trp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanoic acid

C26H41N11O6 (603.3241126)

Ser Arg Trp Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

Ser Trp Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

Trp Asp Lys Arg

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carboxypropanamido]hexanamido]-5-carbamimidamidopentanoic acid

C27H41N9O7 (603.3128796000001)

Trp Asp Arg Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carboxypropanamido]-5-carbamimidamidopentanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Trp Lys Asp Arg

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-3-carboxypropanamido]-5-carbamimidamidopentanoic acid

C27H41N9O7 (603.3128796000001)

Trp Lys Arg Asp

(2S)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]hexanamido]-5-carbamimidamidopentanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Trp Arg Asp Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-carboxypropanamido]hexanoic acid

C27H41N9O7 (603.3128796000001)

Trp Arg Lys Asp

(2S)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]hexanamido]butanedioic acid

C27H41N9O7 (603.3128796000001)

Trp Arg Arg Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanoic acid

C26H41N11O6 (603.3241126)

Trp Arg Ser Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-5-carbamimidamidopentanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

Trp Ser Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C26H41N11O6 (603.3241126)

EELIT

Glu Glu Leu Ile Thr

C26H45N5O11 (603.311542)

Benzonatate

benzonatate (2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)-benzoate

C30H53NO11 (603.3618428)

R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents

Janthitrem E

8-(2-hydroxypropan-2-yl)-2,3,23,23,25,25-hexamethyl-7,24-dioxa-31-azaoctacyclo[15.14.0.0^{2,15}.0^{3,12}.0^{6,11}.0^{18,30}.0^{20,28}.0^{22,27}]hentriaconta-1(17),10,18,20(28),26,29-hexaene-9,12,21-triol

C37H49NO6 (603.3559694)

Fumonisin AK1

2-{2-[(19-acetamido-11,16,18-trihydroxy-5,9-dimethyl-6-oxoicosan-7-yl)oxy]-2-oxoethyl}butanedioic acid

C30H53NO11 (603.3618428)

(R,R)-(-)-N,N-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminocobalt(II)

C36H52CoN2O2 (603.3360552)

Salmeterol Xinafoate

C36H45NO7 (603.3195860000001)

D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents Salmeterol (GR 33343X) xinafoate is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1].